ORMP
Price
$2.17
Change
-$0.11 (-4.82%)
Updated
Jun 5, 11:46 AM (EDT)
Capitalization
93.14M
69 days until earnings call
PTGX
Price
$53.40
Change
+$1.87 (+3.63%)
Updated
Jun 5, 12:45 PM (EDT)
Capitalization
3.19B
56 days until earnings call
Interact to see
Advertisement

ORMP vs PTGX

Header iconORMP vs PTGX Comparison
Open Charts ORMP vs PTGXBanner chart's image
Oramed Pharmaceuticals
Price$2.17
Change-$0.11 (-4.82%)
Volume$100
Capitalization93.14M
Protagonist Therapeutics
Price$53.40
Change+$1.87 (+3.63%)
Volume$200
Capitalization3.19B
ORMP vs PTGX Comparison Chart
Loading...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ORMP vs. PTGX commentary
Jun 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORMP is a Hold and PTGX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 05, 2025
Stock price -- (ORMP: $2.28 vs. PTGX: $51.53)
Brand notoriety: ORMP and PTGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ORMP: 59% vs. PTGX: 67%
Market capitalization -- ORMP: $93.14M vs. PTGX: $3.19B
ORMP [@Biotechnology] is valued at $93.14M. PTGX’s [@Biotechnology] market capitalization is $3.19B. The market cap for tickers in the [@Biotechnology] industry ranges from $318.09B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ORMP’s FA Score shows that 0 FA rating(s) are green whilePTGX’s FA Score has 2 green FA rating(s).

  • ORMP’s FA Score: 0 green, 5 red.
  • PTGX’s FA Score: 2 green, 3 red.
According to our system of comparison, PTGX is a better buy in the long-term than ORMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ORMP’s TA Score shows that 5 TA indicator(s) are bullish while PTGX’s TA Score has 5 bullish TA indicator(s).

  • ORMP’s TA Score: 5 bullish, 5 bearish.
  • PTGX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, PTGX is a better buy in the short-term than ORMP.

Price Growth

ORMP (@Biotechnology) experienced а +5.56% price change this week, while PTGX (@Biotechnology) price change was +12.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.05%. For the same industry, the average monthly price growth was +10.91%, and the average quarterly price growth was -1.52%.

Reported Earning Dates

ORMP is expected to report earnings on Aug 13, 2025.

PTGX is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+5.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTGX($3.19B) has a higher market cap than ORMP($93.1M). PTGX has higher P/E ratio than ORMP: PTGX (66.06) vs ORMP (20.91). PTGX YTD gains are higher at: 33.497 vs. ORMP (-5.785). PTGX has higher annual earnings (EBITDA): 30.1M vs. ORMP (9.44M). PTGX has more cash in the bank: 574M vs. ORMP (142M). ORMP has less debt than PTGX: ORMP (429K) vs PTGX (11.4M). PTGX has higher revenues than ORMP: PTGX (208M) vs ORMP (0).
ORMPPTGXORMP / PTGX
Capitalization93.1M3.19B3%
EBITDA9.44M30.1M31%
Gain YTD-5.78533.497-17%
P/E Ratio20.9166.0632%
Revenue0208M-
Total Cash142M574M25%
Total Debt429K11.4M4%
FUNDAMENTALS RATINGS
ORMP vs PTGX: Fundamental Ratings
ORMP
PTGX
OUTLOOK RATING
1..100
1219
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
10045
SMR RATING
1..100
7927
PRICE GROWTH RATING
1..100
5938
P/E GROWTH RATING
1..100
492
SEASONALITY SCORE
1..100
42n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (58) in the Pharmaceuticals Other industry is in the same range as PTGX (79) in the Biotechnology industry. This means that ORMP’s stock grew similarly to PTGX’s over the last 12 months.

PTGX's Profit vs Risk Rating (45) in the Biotechnology industry is somewhat better than the same rating for ORMP (100) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew somewhat faster than ORMP’s over the last 12 months.

PTGX's SMR Rating (27) in the Biotechnology industry is somewhat better than the same rating for ORMP (79) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew somewhat faster than ORMP’s over the last 12 months.

PTGX's Price Growth Rating (38) in the Biotechnology industry is in the same range as ORMP (59) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew similarly to ORMP’s over the last 12 months.

PTGX's P/E Growth Rating (2) in the Biotechnology industry is somewhat better than the same rating for ORMP (49) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew somewhat faster than ORMP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ORMPPTGX
RSI
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
67%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 18 days ago
84%
Bearish Trend 23 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
87%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RFNEX85.520.19
+0.22%
American Funds Fundamental Invs R4
SSMGX63.54N/A
N/A
Sit Small Cap Growth
FEAIX27.91N/A
N/A
First Eagle Rising Dividend Fund I
GCTRX47.25N/A
N/A
Goldman Sachs US Tax-Managed Eq R6
VYCIX25.41N/A
N/A
Voya Corporate Leaders 100 W